CVS Sells Omnicare Business to GenieRx

Another major chapter in the ongoing transformation of CVS Health is officially closing.

This week, a U.S. bankruptcy court approved the sale of CVS-owned long-term care pharmacy giant Omnicare to GenieRx Holdings in a deal reportedly valued at roughly $250 million.

For CVS, this isn’t just another corporate divestiture. It’s the latest move in a years-long effort to reshape the company after mounting legal pressure, operational struggles, and changing healthcare economics turned what was once viewed as a strategic acquisition into a massive headache.

And honestly? Omnicare went from “future of healthcare expansion” to “please remove this from our balance sheet” remarkably fast.

From $12.7 Billion Acquisition to Bankruptcy Court

Back in 2015, CVS acquired Omnicare for more than $12 billion, hoping to dominate the growing long-term care pharmacy market tied to nursing homes, assisted living facilities, and senior care operations. At the time, the deal was pitched as a smart aging-population play that would deepen CVS’s healthcare ecosystem.

Instead, the business became increasingly difficult to manage.

Over the last several years, Omnicare faced declining reimbursement rates, operational pressure inside long-term care facilities, labor shortages, and major legal battles. The biggest blow came after a federal whistleblower case accused Omnicare of improperly billing government healthcare programs for invalid prescriptions tied to elderly and disabled patients in care facilities.

A federal judge ultimately ordered nearly $949 million in penalties and damages.

That ruling pushed Omnicare into Chapter 11 bankruptcy protection in 2025 while CVS simultaneously looked for a buyer.

Now, that buyer is GenieRx.

Who Exactly Is GenieRx?

GenieRx Holdings is a joint venture backed by private investment firm Milrose Capital and healthcare management group Integro Asset Management, which operates under Integro Healthcare Services.

The company emerged as the “stalking horse bidder” during Omnicare’s court-supervised sale process. In bankruptcy terms, that basically means GenieRx set the baseline bid that other buyers would have had to beat.

Apparently, nobody came in with a better offer.

The approved deal includes approximately $250 million in cash along with the assumption of certain liabilities.

Why This Matters Beyond CVS

This sale says a lot about where healthcare is heading.

The long-term care pharmacy business once looked like a guaranteed growth machine because of America’s aging population. But the reality has become far more complicated. Operators are squeezed by government reimbursement cuts, rising labor costs, regulatory scrutiny, and increasing legal exposure.

Large healthcare conglomerates are also learning that simply buying more healthcare assets does not automatically create efficiency.

CVS has spent the last few years aggressively reshaping itself through store closures, operational restructuring, healthcare service integration, and portfolio cleanup. Omnicare simply no longer fit the vision.

The company appears more focused on consumer healthcare, pharmacy benefits, insurance integration, and primary care expansion than managing a legally troubled long-term care pharmacy network.

CVS Has Been in the Headlines a Lot Lately

If you’ve been following healthcare and pharmacy news, this probably feels familiar.

CVS has spent the last couple of years navigating intense pressure from regulators, investors, lawsuits, pharmacy competition, reimbursement changes, and broader shifts in the healthcare landscape.

We’ve covered several CVS-related stories recently on This Newsroom, including:

CVS restructuring and broader pharmacy industry shifts
Healthcare retail competition and changing consumer behavior
The growing pressure on legacy healthcare giants adapting to AI, automation, and modern care delivery

You can read more coverage here:

This Newsroom – CVS Coverage
This Newsroom – Healthcare News
This Newsroom – Business News

The Bigger Picture

The Omnicare story is one of those corporate cautionary tales that business schools will probably dissect for years.

A multibillion-dollar acquisition designed to dominate healthcare aging trends eventually ended up in bankruptcy court and sold for a fraction of its original value.

That doesn’t necessarily mean CVS is collapsing. Far from it. The company is still one of the most powerful healthcare organizations in America. But it does show how brutally difficult healthcare operations can become when regulation, litigation, aging infrastructure, and changing economics collide all at once.

Healthcare may be “essential,” but that does not make it simple, stable, or endlessly profitable.

And in 2026, even the giants are being forced to rethink everything.